Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biocryst Pharma Inc (BCRX)

11.44   -0.43 (-3.62%) 12-05 00:48
Open: 11.845 Pre. Close: 11.87
High: 11.97 Low: 11.22
Volume: 2,277,585 Market Cap: 2,058M
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.004 - 12.07 12.07 - 12.124
Low: 11.022 - 11.113 11.113 - 11.186
Close: 11.305 - 11.441 11.441 - 11.552

Technical analysis

as of: 2021-12-03 4:42:00 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 16.18     One year: 18.08
Support: Support1: 11.22    Support2: 9.34
Resistance: Resistance1: 13.85    Resistance2: 15.48
Pivot: 12.07
Moving Average: MA(5): 11.82     MA(20): 12.18
MA(100): 14.66     MA(250): 12.95
MACD: MACD(12,26): -0.52     Signal(9): -0.53
Stochastic oscillator: %K(14,3): 14.92     %D(3): 23.34
RSI: RSI(14): 37.45
52-week: High: 18.48  Low: 6.83  Change(%): 49.3
Average Vol(K): 3-Month: 273729  10-Days: 275971

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
BCRX has closed above bottom band by 8.8%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to BCRX's normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 03 Dec 2021
BioCryst announces inducement grants to 11 new employees - Seeking Alpha

Tue, 30 Nov 2021
Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics - Nasdaq

Mon, 29 Nov 2021
3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire - The Motley Fool

Mon, 22 Nov 2021
Health Care Sector Update for 11/22/2021: BCRX,RPRX,ALNY,AFMD,AUPH - Nasdaq

Mon, 22 Nov 2021
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals - Yahoo Finance

Fri, 12 Nov 2021
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 180
Shares Float (M) 166
% Held by Insiders 0.90
% Held by Institutions 59.95
Shares Short (K) 18,970
Shares Short P. Month (K) 18,980

Stock Financials

EPS -1.270
EPS Est This Year -0.750
EPS Est Next Year -0.780
Book Value (p.s.) -0.590
Profit Margin -198.88
Operating Margin -156.06
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth 571.8
Gross Profit (p.s.) -0.594
Sales Per Share 0.634
EBITDA (p.s.) -0.985
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -9.01
PEG Ratio
Price to Book value -19.39
Price to Sales 18.04
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.